GSK Dirección

Dirección controles de criterios 2/4

El CEO de GSK es Emma Walmsley , nombrado en Apr 2017, tiene una permanencia de 7.58 años. compensación anual total es £12.72M, compuesta por 10.3% salario y 89.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.04% de las acciones de la empresa, por valor de $27.38M. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 3.2 años, respectivamente.

Información clave

Emma Walmsley

Chief Executive Officer (CEO)

UK£12.7m

Compensación total

Porcentaje del salario del CEO	10.3%
Permanencia del CEO	7.6yrs
Participación del CEO	0.04%
Permanencia media de la dirección	6yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emma Walmsley en comparación con los beneficios de GSK?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	UK£3b
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Compensación vs. Mercado: La compensación total de Emma($USD15.94M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD5.74M).

Compensación vs. Ingresos: La compensación de Emma ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Emma Walmsley (55 yo)

7.6yrs

Permanencia

UK£12,718,000

Compensación

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emma Walmsley	CEO & Director	7.6yrs	UK£12.72m	0.040% $ 27.4m
Julie Brown	CFO & Executive Director	1.6yrs	UK£5.14m	0.0024% $ 1.7m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.8yrs	sin datos	sin datos
Tony Wood	Chief Scientific Officer and Head of R&D	2.3yrs	sin datos	sin datos
Sarah Elton-Farr	Head of Investor Relations	no data	sin datos	sin datos
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.3yrs	sin datos	sin datos
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.7yrs	sin datos	sin datos
David Redfern	President of Corporate Development	no data	sin datos	sin datos
Diana Conrad	Chief People Officer	5.6yrs	sin datos	sin datos
Philip Thomson	President of Global Affairs	7.6yrs	sin datos	0.0057% $ 3.9m
Luke Miels	Chief Commercial Officer	7.2yrs	sin datos	sin datos
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6.4yrs	sin datos	sin datos

6.0yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GSKD es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Emma Walmsley	CEO & Director	7.8yrs	UK£12.72m	0.040% $ 27.4m
Julie Brown	CFO & Executive Director	1.5yrs	UK£5.14m	0.0024% $ 1.7m
Jonathan Symonds	Non-Executive Chairman	5.2yrs	UK£765.00k	0.0020% $ 1.4m
Vishal Sikka	Independent Non-Executive Director	2.3yrs	UK£147.00k	0.00036% $ 247.0k
Hal Barron	Non-Executive Director	6.8yrs	UK£356.92k	0.032% $ 22.1m
Harry Dietz	Independent Non-Executive Director	2.8yrs	UK£207.09k	0.00016% $ 109.8k
Anne Beal	Independent Non-Executive Director	3.5yrs	UK£174.93k	0.00017% $ 116.7k
Wendy Mira Becker	Independent Non-Executive Director	1.1yrs	UK£32.00k	0.000040% $ 27.4k
Charles Bancroft	Senior Independent Non-Executive Director	4.5yrs	UK£323.00k	0.0014% $ 981.2k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	sin datos	0.000030% $ 20.6k
Elizabeth Anderson	Independent Non-Executive Director	2.2yrs	UK£127.86k	0.000090% $ 61.8k
Jesse Goodman	Independent Non-Executive Director	8.8yrs	UK£173.36k	0.00073% $ 500.9k

3.2yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de GSKD se considera experimentada (3.2 años de antigüedad promedio).

GSK Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Gsk plc Announces Board Committee Changes

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

Recent updates

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad